BioXcel Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BTAI and other ETFs, options, and stocks.

About BTAI

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. 

CEO
Vimal D. Mehta
CEOVimal D. Mehta
Employees
29
Employees29
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2017
Founded2017
Employees
29
Employees29

BTAI Key Statistics

Market cap
30.73M
Market cap30.73M
Price-Earnings ratio
-0.16
Price-Earnings ratio-0.16
Dividend yield
Dividend yield
Average volume
966.18K
Average volume966.18K
High today
$1.15
High today$1.15
Low today
$1.12
Low today$1.12
Open price
$1.21
Open price$1.21
Volume
10.89K
Volume10.89K
52 Week high
$8.08
52 Week high$8.08
52 Week low
$1.08
52 Week low$1.08

Stock Snapshot

The current BioXcel Therapeutics(BTAI) stock price is $1.15, with a market capitalization of 30.73M. The stock trades at a price-to-earnings (P/E) ratio of -0.16.

During the trading session on 2026-04-07, BioXcel Therapeutics(BTAI) shares reached a daily high of $1.15 and a low of $1.12. At a current price of $1.15, the stock is +2.7% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 10.89K, compared to an average daily volume of 966.18K.

Over the past 52 weeks, BioXcel Therapeutics(BTAI) stock has traded between a high of $8.08 and a low of $1.08.

Over the past 52 weeks, BioXcel Therapeutics(BTAI) stock has traded between a high of $8.08 and a low of $1.08.

BTAI News

TipRanks 6d
FDA Accepts BioXcel sNDA for At-Home IGALMI Use

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 6d
BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

BioXcel Therapeutics (BTAI) announced that the FDA has accepted its supplemental new drug application, or sNDA, for approval of Igalmi for at-home use in the ac...

People also own

Based on the portfolios of people who own BTAI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.